Sumą deklaruoja pati organizacija Skaidrumo registre; institucijos jos netikrina.
Susitikimai pagal metus
202042021420254
Šaltinis: Europos Komisijos skelbiami susitikimai, sutapatinti pagal skaidrumo registro numerį. n = 12 susitikimų; x — metai pagal susitikimo datą, y — susitikimų skaičius.
Susitikimai su Europos Komisija
Skelbiami tik susitikimai su Komisijos nariais, jų kabinetais ir generaliniais direktoriais. Susitikimai žemesniu lygiu ir daugelis kontaktų Parlamente bei Taryboje į registrą nepatenka.
2024-02-08 · Report on the application of the General Data Protection Regulation ↗ originalus šaltinis
SIOPE is the single united organization of paediatric oncology clinicians and academia in Europe with over 2,500 members in 35 countries. Paediatric cancers are rare diseases but represent a major aggregate health burden - the first cause of death by disease in children older than 1 year in Europe and an important contributor to long-term morbidity in most of the estimated 500,000 survivors. Cross-border collaboration in paediatric oncology is required to overcome small sample sizes in research and exchange specialist expertise in care delivery. Data sharing is systematically accompanied by strong measures to keep personal data safe, such as pseudonymisation, state-of-the-art technologies…
Kokias ES temas nurodo sekanti
SIOPE focuses on policies and programmes addressing healthcare organization & delivery and health research, in particular in the areas of childhood cancer as well as cancer (overall) and rare diseases. Main EU initiatives followed as of October 2025: - Europe’s Beating Cancer Plan across its initiatives e.g. European Cancer Information Systems & Inequalities Registry - EU Cancer Mission - Pharmaceutical Strategy for Europe - Critical Medicine Act - EU Lifesciences Strategy - Heath Technology Assessment - European Reference Networks - Horizon Europe - EU4Health - Multi-annual Financial Framework - European Health Data Space - Health Emergency Preparedness and Response Main EU legislative files followed as of October 2025: - Revision of the EU Pharmaceutical Legislation including as pertaining to Regulation and Directive on Medicinal products for human use, Regulation